Capricor Therapeutics
Market Cap
US$7.4m
Last Updated
2019/11/15 00:07 UTC
Data Sources
Company Financials +
Executive Summary
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions.
Snowflake
Fundamentals
Adequate balance sheet and overvalued.
Similar Companies
Share Price & News
How has Capricor Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CAPR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-20.5%
CAPR
0.7%
US Biotechs
0.2%
US Market
1 Year Return
-81.0%
CAPR
5.6%
US Biotechs
12.2%
US Market
Return vs Industry: CAPR underperformed the US Biotechs industry which returned 5.6% over the past year.
Return vs Market: CAPR underperformed the US Market which returned 12.2% over the past year.
Shareholder returns
| CAPR | Industry | Market | |
|---|---|---|---|
| 7 Day | -20.5% | 0.7% | 0.2% |
| 30 Day | -38.4% | 8.3% | 3.5% |
| 90 Day | -40.1% | 4.7% | 6.3% |
| 1 Year | -81.0%-81.0% | 6.5%5.6% | 14.7%12.2% |
| 3 Year | -94.4%-94.4% | 13.9%10.3% | 47.8%38.3% |
| 5 Year | -95.4%-95.4% | 4.7%-0.2% | 62.1%44.1% |
Price Volatility Vs. Market
How volatile is Capricor Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Did Changing Sentiment Drive Capricor Therapeutics's (NASDAQ:CAPR) Share Price Down A Painful 94%?1 month ago | Simply Wall St
Before You Buy Capricor Therapeutics, Inc. (NASDAQ:CAPR), Consider Its Volatility1 month ago | Simply Wall St
Can Capricor Therapeutics (NASDAQ:CAPR) Afford To Invest In Growth?Valuation
Is Capricor Therapeutics undervalued compared to its fair value and its price relative to the market?
2.57x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAPR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: CAPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAPR is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.8x).
Next Steps
Future Growth
How is Capricor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
9.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAPR's revenue is expected to decline over the next 3 years (-14.4% per year).
High Growth Revenue: CAPR's revenue is forecast to decline over the next 3 years (-14.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CAPR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Capricor Therapeutics performed over the past 5 years?
4.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: Insufficient data to determine if CAPR has high quality earnings.
Growing Profit Margin: CAPR's current net profit margins (-793.1%) are lower than last year (111.4%).
Past Earnings Growth Analysis
Earnings Trend: CAPR is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).
Return on Equity
High ROE: CAPR has a negative Return on Equity (-506.05%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Capricor Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CAPR's short term assets ($6.6M) exceeds its short term liabilities ($1.6M)
Long Term Liabilities: CAPR's short term assets (6.6M) exceeds its long term liabilities (3.4M)
Debt to Equity History and Analysis
Debt Level: CAPR is debt free.
Reducing Debt: CAPR currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Inventory Level: CAPR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CAPR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAPR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CAPR has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.4% each year.
Next Steps
Dividend
What is Capricor Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Capricor Therapeutics's salary, the management and board of directors tenure and is there insider trading?
4.8yrs
Average management tenure
CEO
Linda Marbán (56yo)
9.8yrs
Tenure
US$377,471
Compensation
Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be ...
CEO Compensation Analysis
Compensation vs Market: Linda's total compensation ($USD377.47K) is about average for companies of similar size in the US market ($USD510.82K).
Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.8yrs
Average Tenure
56yo
Average Age
Experienced Management: CAPR's management team is considered experienced (4.8 years average tenure).
Board Age and Tenure
6.0yrs
Average Tenure
67.5yo
Average Age
Experienced Board: CAPR's board of directors are considered experienced (6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.8%.
Management Team
Frank Litvack (63yo)
Executive Chairman
- Tenure: 0yrs
- Compensation: US$206.62k
Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Board
- Tenure: 0yrs
Linda Marbán (56yo)
Co-Founder
- Tenure: 9.8yrs
- Compensation: US$377.47k
Karen Krasney (66yo)
Executive VP
- Tenure: 7.7yrs
- Compensation: US$351.89k
Anthony Bergmann (33yo)
CFO & Corporate Treasurer
- Tenure: 1.8yrs
- Compensation: US$273.70k
Deborah Ascheim (54yo)
Consultant
- Tenure: 1yrs
- Compensation: US$364.90k
Catherine Kelleher
Consultant
- Tenure: 0yrs
Board Members
George Dunbar (72yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$40.28k
Duke Collier (72yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$43.85k
Frank Litvack (63yo)
Executive Chairman
- Tenure: 0yrs
- Compensation: US$206.62k
David Musket (61yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$54.57k
Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Board
- Tenure: 0yrs
Francesco Muntoni
Member of Scientific Advisory Board
- Tenure: 0yrs
Linda Marbán (56yo)
Co-Founder
- Tenure: 9.8yrs
- Compensation: US$377.47k
Thomas Voit
Member of Scientific Advisory Board
- Tenure: 0yrs
Louis Manzo (81yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$36.70k
Ron Victor
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Capricor Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Capricor Therapeutics, Inc.
- Ticker: CAPR
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.431m
- Shares outstanding: 4.25m
- Website: https://www.capricor.com
Number of Employees
Location
- Capricor Therapeutics, Inc.
- 8840 Wilshire Boulevard
- 2nd Floor
- Beverly Hills
- California
- 90211
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CAPR | NasdaqCM (Nasdaq Capital Market) | Yes | New Common Stock | US | USD | Nov 2013 |
| 4LN2 | DB (Deutsche Boerse AG) | Yes | New Common Stock | DE | EUR | Nov 2013 |
Biography
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular d ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/15 00:07 |
| End of Day Share Price | 2019/11/14 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.